CD8A and plasma cell myeloma: Pre-clinical studies have demonstrated that a single dose of ALT-803 was able to eliminate well-established primary myeloma cells in the bone marrow and to further reject tumor re-challenge due to expansion of CD44hi memory CD8+ T cells [45].